A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

NCT00144482•Chugai Pharmaceutical

Summary

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Eligibility

Age

20 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cancer patients

Exclusion Criteria

•a history of myocardial, cerebral or pulmonary infarction
•severe hypertension beyond control by drugs

Key Dates

Start Date

December 1, 2003

Primary Completion Date

March 1, 2005

Completion Date

August 1, 2005

Last Updated

February 2, 2009

Enrollment

122

ACTUAL participants

Conditions

Chemotherapy Induced Anemia

Interventions

recombinant human erythropoietin

DRUG

recombinant human erythropoietin placebo

DRUG

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

NCT00931606

Chemotherapy Induced Anemia

View study

COMPLETEDPHASE1

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240

Patients With Chemotherapy Induced Anemia (CIA)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions